Chumakov's Vaccine Against Coronavirus And Its Composition

Chumakov's Vaccine Against Coronavirus And Its Composition
Chumakov's Vaccine Against Coronavirus And Its Composition

Video: Chumakov's Vaccine Against Coronavirus And Its Composition

Отличия серверных жестких дисков от десктопных
Video: Questions Arise About COVID-19 Vaccines Amid High-Profile Breakthrough Cases 2023, February
Anonim
Image
Image

Three vaccines against COVID-19 have been developed in Russia. They are already being vaccinated with Sputnik V, and in March it is planned to use a drug from the Vector Center called EpiVacCorona. There is also Chumakov's vaccine against coronavirus. Its registration is scheduled for February 2021.

Features of the composition of the Chumakov vaccine

The new drug was developed by the Chumakov Center. Its trade name is KoviVak. After the official registration of the drug, it is planned that it will be used to vaccinate the population. According to Deputy Prime Minister Tatyana Golikova, Chumakov's vaccine can be used from April. Until that time, she will pass all stages of testing and registration with the Ministry of Health.

The M.P. Chumakov Center is an authoritative medical organization recognized in the scientific world. She is engaged in the study of viral hepatitis, tick-borne encephalitis, coronavirus.

Chumakov's vaccine differs in composition from other similar drugs. The drug contains the whole inactivated virus, and not its individual parts. This allows to achieve the effectiveness of action up to 100%.

The manufacturing technology of such vaccines has been tested by many years of experience and research. During the tests, the volunteers did not show any side effects. Even the traditional symptoms in such cases - weakness and fever - did not appear.

Vaccine instructions

The drug "KoviVak" has not passed official registration, for this reason, instructions for its use have not yet been published. At a briefing by members of the Russian Government on January 18, the procedure for using the drug was announced.

The vaccination is done twice with an interval of 14 days. It is known that a new drug can be transported and stored at temperatures from +2 to + 8 ° C. The formation of stable immunity occurs on the 21st day after the second injection.

Chumakov's vaccine will be effective against COVID-19 and its strains.

There are no plans to sell Chumakov's vaccine in Russia. It will be for free general vaccinations. More accurate information will be known after registration, which is scheduled for mid-February.

Interesting! How does the coronavirus vaccine affect reproductive function?

Forecasts

Scientists speculate about the successful use of the Chumakov Center vaccine. They predict high rates of drug efficacy. Their opinions are based on the results of a study on the CoviVac vaccine. In the first phase of the research, over 200 people took part in the trials. According to the results, there were no side effects on the administration of the drug.

The employees of the M.P. Chumakov Center, who developed the vaccine, claim that the drug is safe for the elderly, has no age restrictions. This can be a salvation for most citizens, as the varieties of the main virus begin to actively spread.

Contraindications for vaccination

There are certain limitations for drugs that affect the immune system. Chumakov's vaccine also has contraindications:

exacerbation of chronic diseases; diseases of infectious and non-infectious origin in the acute period; autoimmune diseases; pregnancy, lactation period; acute respiratory diseases, infections of the digestive system with fever; age restrictions (will be known after registration of the drug).

Vaccination is allowed 2-4 weeks after temperature normalization, recovery or remission. Before being vaccinated, a person should be examined by a doctor to determine their health status.

Immunization against coronavirus is possible for those who have not received other vaccinations for a month. This is especially true for the flu shot.

There is a group of people for whom vaccination is not contraindicated, but it is carried out with caution and under the supervision of a doctor after careful preparation. We are talking about people with a history of such diseases and conditions:

chronic kidney disease; liver pathology; sugar

diabetes

; diseases of the nervous system, such as epilepsy; pathologies of the cardiovascular system, for example, stroke, heart attack, myocarditis, ischemia; immunodeficiency of primary and secondary forms; autoimmune diseases; metabolic syndrome; pathologies of the respiratory system, for example, chronic obstructive pulmonary disease, bronchial asthma; allergy; eczema; atopic dermatitis.

People with cancer should not be vaccinated 2 weeks before or during chemotherapy. There should be a break of 3 months between the course of systemic cancer treatment and vaccination. After vaccination, be sure to wear a mask. Immunity will only form 3 weeks after the second injection.

Vaccination news

Deputy Prime Minister Tatyana Golikova expressed in the media that with the registration of Chumakov's vaccine, Russians will have the opportunity to choose a drug for immunization. According to her, at the end of January, the second drug for coronavirus will be delivered to regional medical institutions, more precisely, to the Rostov and Tula regions. This is "EpiVacCorona", which has also passed all the necessary studies and tests, has shown high efficiency in protecting the body from coronavirus infection.

According to the Public Opinion Foundation, 42% of Russians are going to be vaccinated against the coronavirus.

Oksana Drapkina, director of the National Medical Research Center of Therapy and Preventive Medicine, said that those who have had a coronavirus infection do not need to be vaccinated. The result of an analysis of the level of antibodies of class G in the blood may indicate a past illness, it will be elevated. Such an analysis is rented in a polyclinic free of charge under the compulsory medical insurance policy. You can also take it for a fee in any private laboratory.

The American company Pfizer and the German company BioNTech, which developed the COVID-19 vaccine, conducted laboratory tests of their drug. They investigated its ability to fight the "British" variant of the coronavirus.

The results were published at the end of January. According to the research results, it turned out that the Pfizer / BioNTech vaccine is capable of neutralizing the mutated virus. This inspired scientists to continue working to improve the effectiveness of their drug.

Outcomes

Scientists around the world are working to create drugs for COVID-19. Chumakov's Russian vaccine against coronavirus will be registered in February and will begin arriving at polyclinics for immunization. Its composition differs from other drugs; as a result of exposure, a more stable immunity is developed. Vaccination with the drug from the Chumakov Center will take place in two stages. Registration of the new drug is expected in February.

Popular by topic